Document Detail

Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy.
MedLine Citation:
PMID:  23369142     Owner:  NLM     Status:  Publisher    
Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it's associated with HF with preserved ejection fraction (HFPEF).
Hakan Altay; Yücel Colkesen
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-15
Journal Detail:
Title:  Endocrine, metabolic & immune disorders drug targets     Volume:  -     ISSN:  2212-3873     ISO Abbreviation:  Endocr Metab Immune Disord Drug Targets     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-2-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101269157     Medline TA:  Endocr Metab Immune Disord Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Cardiology, Baskent University Faculty of Medicine Oymacı sk. No:7, 34662 Altunizade, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Testosterone Deficiency in Male: A Risk Factor for Heart Failure.
Next Document:  The role of n-3 polyunsaturated fatty acids in human heart failure.